SRA737 treatment induces higher levels of γH2AX foci in a dose dependant fashion, in the TP53 MUT H23 NSCLC cells and HT29 CRC cells compared to the corresponding TP53 WT A549 NSCLC and HCT116 CRC cells. The gene discussed is TP53; the disease is non-small cell lung carcinoma.